JP2002502871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002502871A5 JP2002502871A5 JP2000531161A JP2000531161A JP2002502871A5 JP 2002502871 A5 JP2002502871 A5 JP 2002502871A5 JP 2000531161 A JP2000531161 A JP 2000531161A JP 2000531161 A JP2000531161 A JP 2000531161A JP 2002502871 A5 JP2002502871 A5 JP 2002502871A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- subject
- disease
- amino
- propanesulfonic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- LZXHHNKULPHARO-UHFFFAOYSA-M (3,4-dichlorophenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].C1=C(Cl)C(Cl)=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 LZXHHNKULPHARO-UHFFFAOYSA-M 0.000 description 11
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Amino-1-propanesulfonic acid Natural products NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 230000016273 neuron death Effects 0.000 description 6
- 206010029350 Neurotoxicity Diseases 0.000 description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 230000007135 neurotoxicity Effects 0.000 description 4
- 231100000228 neurotoxicity Toxicity 0.000 description 4
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 3
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- FHELRCNMJVEIBX-UHFFFAOYSA-N 3-aminopropane-1-sulfonic acid;sodium Chemical compound [Na].NCCCS(O)(=O)=O FHELRCNMJVEIBX-UHFFFAOYSA-N 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- KMGJRCNLDZGSFX-UHFFFAOYSA-M sodium;3-aminopropane-1-sulfonate Chemical compound [Na+].NCCCS([O-])(=O)=O KMGJRCNLDZGSFX-UHFFFAOYSA-M 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7429598P | 1998-02-11 | 1998-02-11 | |
| US60/074,295 | 1998-02-11 | ||
| US24839699A | 1999-02-10 | 1999-02-10 | |
| US09/248,396 | 1999-02-10 | ||
| PCT/IB1999/000354 WO1999040909A1 (en) | 1998-02-11 | 1999-02-11 | Method for modulating macrophage activation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002502871A JP2002502871A (ja) | 2002-01-29 |
| JP2002502871A5 true JP2002502871A5 (https=) | 2008-11-20 |
| JP4574845B2 JP4574845B2 (ja) | 2010-11-04 |
Family
ID=26755484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000531161A Expired - Lifetime JP4574845B2 (ja) | 1998-02-11 | 1999-02-11 | マクロファージの活性化を調節する方法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1054664B1 (https=) |
| JP (1) | JP4574845B2 (https=) |
| AU (1) | AU2437899A (https=) |
| CA (2) | CA2320224C (https=) |
| CY (1) | CY1113205T1 (https=) |
| DK (1) | DK1054664T3 (https=) |
| ES (1) | ES2392391T3 (https=) |
| IL (1) | IL137751A0 (https=) |
| MX (2) | MXPA00007815A (https=) |
| NZ (2) | NZ550199A (https=) |
| PT (1) | PT1054664E (https=) |
| WO (1) | WO1999040909A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605938A (en) | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| WO1999059571A1 (en) * | 1998-05-15 | 1999-11-25 | Neurochem, Inc. | Use of amyloid inhibitors for modulating neuronal cell death |
| US6310073B1 (en) | 1998-07-28 | 2001-10-30 | Queen's University At Kingston | Methods and compositions to treat glycosaminoglycan-associated molecular interactions |
| CA2369997C (en) * | 1999-04-28 | 2009-11-17 | Queen's University At Kingston | Compositions and methods for treating amyloidosis |
| AU5994900A (en) * | 1999-07-09 | 2001-01-30 | Isis Innovation Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
| IL150374A0 (en) | 1999-12-23 | 2002-12-01 | Neurochem Inc | Compounds and methods for modulating cerebral amyloid angiopathy |
| US7105336B2 (en) * | 2002-10-07 | 2006-09-12 | Biogaia Ab | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter |
| EP1585520A1 (en) * | 2002-12-24 | 2005-10-19 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| CN100571701C (zh) * | 2002-12-24 | 2009-12-23 | 贝卢斯健康(国际）有限公司 | 治疗β淀粉样蛋白相关疾病的治疗性制品 |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US7414076B2 (en) | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| EP1646659B1 (en) * | 2003-06-23 | 2014-05-14 | Kiacta Sàrl | Method for the preparation of 1,3-propane disulfonic acid compounds |
| US7253306B2 (en) | 2003-06-23 | 2007-08-07 | Neurochem (International) Limited | Pharmaceutical drug candidates and methods for preparation thereof |
| WO2006085149A2 (en) | 2004-12-22 | 2006-08-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| TW200716088A (en) * | 2005-04-15 | 2007-05-01 | Neurochem Int Ltd | Formulations and methods for treating amyloidosis |
| RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
| PL2289909T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał |
| EP1968561B8 (en) | 2005-12-22 | 2010-10-20 | Kiacta Sàrl | Treatment of diabetic nephropathy |
| PT2089417E (pt) | 2006-10-12 | 2015-04-14 | Bhi Ltd Partnership | Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| RS53174B (sr) | 2007-10-05 | 2014-06-30 | Genentech Inc. | Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka |
| JP2012517822A (ja) * | 2009-02-19 | 2012-08-09 | ガラパゴス・ナムローゼ・フェンノートシャップ | 炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物 |
| MY159626A (en) * | 2009-09-17 | 2017-01-13 | Bespoke Bioscience Llc | Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| RU2607368C2 (ru) | 2010-07-30 | 2017-01-10 | Ац Иммуне С.А. | Безопасные и функциональные гуманизированные антитела |
| CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| WO2016163886A2 (en) * | 2015-04-10 | 2016-10-13 | Clues2Cure International B.V. | Administration of taurine or an analog thereof for the treatment of nerve cell damage |
| CN109381452A (zh) * | 2017-08-11 | 2019-02-26 | 江西青峰药业有限公司 | 乙基硫酸类化合物的应用及其制备方法 |
| CN109381453A (zh) * | 2017-08-14 | 2019-02-26 | 江西青峰药业有限公司 | 乙基硫酸钾在制备用于预防或治疗炎症性疾病药物中的应用 |
| CN109394746A (zh) * | 2017-08-15 | 2019-03-01 | 江西青峰药业有限公司 | 乙基硫酸铵在制备用于预防或治疗炎症性疾病药物中的应用 |
| US20250345298A1 (en) | 2022-04-28 | 2025-11-13 | Alzheon, Inc. | Apoe4 correctors and methods of use |
| CN120641092A (zh) | 2022-12-02 | 2025-09-12 | 阿尔泽恩股份有限公司 | 用于用曲米沙特治疗神经变性病症的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1144937A (en) * | 1977-12-22 | 1983-04-19 | Dke J.E. Helgstrand | Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections |
| US5087618A (en) * | 1982-05-18 | 1992-02-11 | University Of Florida | Redox carriers for brain-specific drug delivery |
| US5463092A (en) * | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
| US5276059A (en) * | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
| DE69434571T2 (de) * | 1993-03-29 | 2006-08-03 | Queen's University At Kingston, Kingston | Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable Salze zur Behandlung von Amyloidosis |
| US5643562A (en) * | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| NZ550116A (en) * | 1997-08-18 | 2008-03-28 | Neurochem Int Ltd | Phosphono-carboxylate compounds for treating amyloidosis |
| US5869469A (en) * | 1997-08-18 | 1999-02-09 | Queen's University At Kingston | Phosphonocarboxylate compounds for treating amyloidosis |
-
1999
- 1999-02-11 WO PCT/IB1999/000354 patent/WO1999040909A1/en not_active Ceased
- 1999-02-11 AU AU24378/99A patent/AU2437899A/en not_active Abandoned
- 1999-02-11 JP JP2000531161A patent/JP4574845B2/ja not_active Expired - Lifetime
- 1999-02-11 DK DK99903869.8T patent/DK1054664T3/da active
- 1999-02-11 PT PT99903869T patent/PT1054664E/pt unknown
- 1999-02-11 CA CA002320224A patent/CA2320224C/en not_active Expired - Lifetime
- 1999-02-11 ES ES99903869T patent/ES2392391T3/es not_active Expired - Lifetime
- 1999-02-11 NZ NZ550199A patent/NZ550199A/en not_active IP Right Cessation
- 1999-02-11 NZ NZ568553A patent/NZ568553A/en unknown
- 1999-02-11 IL IL13775199A patent/IL137751A0/xx not_active IP Right Cessation
- 1999-02-11 EP EP99903869A patent/EP1054664B1/en not_active Expired - Lifetime
- 1999-02-11 CA CA002632106A patent/CA2632106A1/en not_active Abandoned
- 1999-02-11 MX MXPA00007815A patent/MXPA00007815A/es active IP Right Grant
- 1999-02-11 MX MX2008014823A patent/MX2008014823A/es active IP Right Grant
-
2012
- 2012-10-16 CY CY20121100954T patent/CY1113205T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002502871A5 (https=) | ||
| CA2301378A1 (en) | Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin | |
| IL139229A0 (en) | Drug delivery system comprising a tightly compacted solid medicament stock | |
| CA2307018A1 (en) | Osmotic medicament releasing system | |
| CA2492081A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | |
| CA2326517A1 (en) | New galenic preparations of meloxicam for oral administration | |
| CA2375908A1 (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
| ATE515265T1 (de) | Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen | |
| WO2001039762A3 (en) | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system | |
| WO1997048391A3 (en) | Methods and compositions comprising r-ibuprofen | |
| FR2798065B1 (fr) | Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson | |
| CA2387486A1 (en) | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders | |
| AU2023251499B2 (en) | Combinations of opioids and N-acylethanolamines | |
| AU7425391A (en) | Use of n-alkylated 1, 4-dihydropyridinedicarboxylic acid esters as medicaments, new compounds and processes for their preparation | |
| CA2143610A1 (en) | Use of norastemizole for the treatment of allergic disorders | |
| EP4520394A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2003520193A (ja) | Ｒ（−）−ケトプロフェンを用いる神経障害性疼痛、耳鳴り、およびその他の障害治療のための方法および組成物 | |
| WO2001012214A3 (en) | MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) | |
| MXPA02009603A (es) | Terapias de dosis divididas con actividad de deterioro vascular. | |
| CA2514022A1 (en) | Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders | |
| BR0009327A (pt) | Composição farmacêutica para a terapia de sintomas do trato urinário inferior | |
| CA2469702A1 (en) | Darifenacin for use in the treatment of urgency induced by overactive bladder | |
| WO1997044045A1 (en) | Malatonin in combination with analgesics | |
| CA2515259A1 (en) | Use of acetylsalicylic acid for the treatment of hemorrhoidal disease | |
| RU97104062A (ru) | Применение селегилина для лечения эпилептических заболеваний |